Ana Cobo1, Vicente Serra2, Nicolás Garrido2, Inés Olmo2, Antonio Pellicer2, José Remohí2. 1. Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain. Electronic address: ana.cobo@ivi.es. 2. Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain.
Abstract
OBJECTIVE: To assess outcomes after oocyte vitrification on obstetric and perinatal outcomes compared with those achieved with fresh oocytes. DESIGN: Retrospective cohort study. SETTING: Private university-affiliated IVF center. PATIENT(S): Children born after use of vitrified oocytes (1,027 from 804 pregnancies) and fresh oocytes (1,224 from 996 pregnancies). Singleton and multiples pregnancies from own and donated ova were included. INTERVENTION(S): Oocyte vitrification by the Cryotop method. MAIN OUTCOME MEASURE(S): Pregnancy, delivery, and neonatal outcomes. RESULT(S): Vitrification had no clinically relevant adverse effects on obstetric and perinatal outcomes after adjusting for potential confounders. No differences were found between the vitrified and fresh oocyte groups in the rate of obstetric problems (including diabetes, pregnancy-induced hypertension, preterm birth, anemia, and cholestasis), gestational age at delivery, birth weight, Apgar scores, birth defects, admission to neonatal intensive care unit (ICU), perinatal mortality, and puerperal problems. Only a greater number of invasive procedures (adjusted odds ratio 2.12; 95% confidence interval 1.41-3.20), and a reduced occurrence of urinary tract infection (adjusted odds ratio 0.51; 95% confidence interval 0.28-0.91), were observed in the vitrified oocytes group. CONCLUSION(S): Although our data, the largest series to date, suggest that oocyte vitrification does not increase adverse obstetric and perinatal outcomes in children conceived with vitrified oocytes, further studies with larger samples are required to reinforce our conclusions.
OBJECTIVE: To assess outcomes after oocyte vitrification on obstetric and perinatal outcomes compared with those achieved with fresh oocytes. DESIGN: Retrospective cohort study. SETTING: Private university-affiliated IVF center. PATIENT(S): Children born after use of vitrified oocytes (1,027 from 804 pregnancies) and fresh oocytes (1,224 from 996 pregnancies). Singleton and multiples pregnancies from own and donated ova were included. INTERVENTION(S): Oocyte vitrification by the Cryotop method. MAIN OUTCOME MEASURE(S): Pregnancy, delivery, and neonatal outcomes. RESULT(S): Vitrification had no clinically relevant adverse effects on obstetric and perinatal outcomes after adjusting for potential confounders. No differences were found between the vitrified and fresh oocyte groups in the rate of obstetric problems (including diabetes, pregnancy-induced hypertension, preterm birth, anemia, and cholestasis), gestational age at delivery, birth weight, Apgar scores, birth defects, admission to neonatal intensive care unit (ICU), perinatal mortality, and puerperal problems. Only a greater number of invasive procedures (adjusted odds ratio 2.12; 95% confidence interval 1.41-3.20), and a reduced occurrence of urinary tract infection (adjusted odds ratio 0.51; 95% confidence interval 0.28-0.91), were observed in the vitrified oocytes group. CONCLUSION(S): Although our data, the largest series to date, suggest that oocyte vitrification does not increase adverse obstetric and perinatal outcomes in children conceived with vitrified oocytes, further studies with larger samples are required to reinforce our conclusions.
Authors: Thais S Domingues; Ana Paula Aquino; Bruna Barros; Raquel Mazetto; Mariana Nicolielo; Carolina M Kimati; Talita Devecchi; Tatiana C S Bonetti; Paulo C Serafini; Eduardo L A Motta Journal: J Assist Reprod Genet Date: 2017-08-16 Impact factor: 3.412
Authors: Rani Fritz; Susan Klugman; Harry Lieman; Jay Schulkin; Laura Taouk; Neko Castleberry; Erkan Buyuk Journal: J Assist Reprod Genet Date: 2018-08-02 Impact factor: 3.412